Gilead Sciences Canada News and Activities

Gilead Sciences Canada is owned by Gilead Sciences.

Gilead Sciences is one of the...

• Forbes Global 2000 (#233);
• Fortune 500 (#153);
• Nasdaq 100;
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Gilead Sciences is a company listed under the stock ticker GILD (US).

Gilead Sciences has a direct presence in 7 countries.

Gilead Sciences has 9 subsidiaries including Arcellx, Gilead Sciences Canada and Gilead Sciences EMEA.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Gilead Sciences.

• Gilead Sciences has acquired Tubulis (posted on May 21 2026).
• Gilead Sciences has acquired Arcellx (posted on April 28 2026).
• Gilead Sciences has announced the acquisition of Tubulis  (posted on April 16 2026).
• Gilead Sciences has announced the acquisition of Ouro Medicines  (posted on March 24 2026).
• See more news about Gilead Sciences Hide news involving Gilead Sciences

View the org chart displaying its 10 main executives

Most searched biographies at Gilead Sciences Canada

• Jessica Chang, Head of Human Resources
• Bobby Sutherland, Senior Director, Government Affairs
• Scott Curley, Head, Commercial Operations

Popular executive movements at Gilead Sciences

• Scott Nunn, Senior Director, Packaging and Labeling Development, has left the company  (posted on June 18 2026).
• Kimberly Jablonski has joined the company as Senior Vice President, Global Legal Business Partners  (posted on June 18 2026).
• Jeffrey Deming has joined the company as Executive, Medical Affairs Governance and Operations  (posted on June 18 2026).

Click here to view some more movements at Gilead Sciences

Create your alert
to follow the executive moves at Gilead Sciences Canada.

Gilead Sciences has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Gilead Sciences Canada

Social media about Gilead Sciences Canada

• Gilead Sciences Canada on Wikipedia, Google News & Yahoo Finance
• Gilead Sciences Canada on LinkedIn, X (Twitter) & YouTube